drugset / Trial / NCT03102125

Allograft Dysfunction in Heart Transplant

NCT03102125

Phase 4 Recruiting 376 enrolled Paul Kim
Non-randomizedParallel-groupSingle-blindDiagnostic

Summary

The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.

Timeline

Start
2019-10-01
Primary completion
2027-01-01
Completion
2027-01-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Regadenoson Diagnostic / imaging agent 0.4 mg Intravenous

Indications